FMP
Infinity Pharmaceuticals, Inc.
INFI
NASDAQ
Inactive Equity
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
0.008 USD
-0.0088 (-110%)
Historical Prices
From:
To:
About
ceo
Mr. Seth A. Tasker J.D.
sector
Healthcare
industry
Biotechnology
website
https://www.infi.comexchange
NASDAQ
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, ...
CIK
0001113148
ISIN
US45665G3039
CUSIP
45665G303
Address
1100 Massachusetts Avenue
Phone
617 453 1000
Country
US
Employee
30
IPO Date
Jul 28, 2000
Financial Statement
Earnings
INFI Financial Summary
CIK
0001113148
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45665G303
ISIN
US45665G3039
Country
US
Price
0.01
Beta
1.38
Volume Avg.
3.98M
Market Cap
726.09k
Shares
-
52-Week
0.0056-1.3
DCF
2.54
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.02
P/B
-
Website
https://www.infi.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest INFI News
InvestorPlace
Aug 8, 2023
Why Is Infinity Pharmaceuticals (INFI) Stock Up 84% Today?
Infinity Pharmaceuticals (NASDAQ: INFI ) stock is rocketing higher on Tuesday morning despite a lack of news from the biopharmaceutical company. Investors seeking out news concerning shares of INFI stock this morning won't find any new press releases or filings.
Business Wire
Jun 15, 2023
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast P...
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern.
Zacks Investment Research
Mar 28, 2023
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenu...
Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
Mar 28, 2023
Will Infinity Pharmaceuticals (INFI) Report Negative Q4 Earn...
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga
Mar 14, 2023
Top 5 Health Care Stocks Which Could Rescue Your Portfolio T...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Zacks Investment Research
Nov 17, 2022
Down 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe...
The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Seeking Alpha
Nov 14, 2022
Infinity Pharmaceuticals, Inc. (INFI) Q3 2022 Earnings Call ...
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman and Chief Executive Officer Robert Ilaria - Chief Medical Officer Larry Bloch - President Conference Call Participants Edward Tenthoff - Piper Sandler Soumit Roy - Jones Research Mayank Mamtani - B. Riley Operator Ladies and gentlemen, thank you for standing by.
Business Wire
Nov 7, 2022
Infinity Pharmaceuticals Announces the Date of Its Third Qua...
CAMBRIDGE, Mass.
